Discussing our other top DEGs in the context of other cancers, increased expression of complement genes C1QA and C1QB at week 16 of mantle cell lymphoma treatment by Venetoclax and Ibrutinib was significantly associated with a worse prognosis [60], illustrating that C1QA and C1QB may be associated with resistance to cancer drugs. The gene discussed is C1QA; the disease is cancer.